Home/Biosimilar Atlas/Etanercept/Cipla etanercept

Cipla etanercept

Etanercept biosimilar developed by Not stated in the CDSCO list. Reference product Enbrel.

Brands by market: Brand not published by CDSCO (India, import) ยท Commercial partner or holder: Cipla (import)
FDAnot listed
EMAnot listed
CDSCOOct 2012permitted
EDEnot listed

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Cipla Limited
Pathway
Import and marketing permission
Approved
Oct 2012
Application or permission
Import permission
Indications as licensed
Rheumatoid arthritis, alone or with methotrexate
Presentations
25 mg lyophilised vial
Note
First etanercept permitted in India.
Source
S013
EDE

United Arab Emirates

Not listed by EDE.

Chronology

Sources

All etanercept biosimilars

Planning etanercept biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.